PROS1 and COVID-19: Investigations of several sartans and bisartans were undertaken to determine if these compounds (i) bind to ACE2, (ii) inhibit the ACE2 enzyme catalysis of AngII to angiotensin (1–7), and (iii) inhibit the binding of COVID-19 S-protein to ACE2.